Antibody Information
General Information of This Antibody
| Antibody ID | ANI0JYZKZ |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-hCD74 clone11 |
|||||
| Synonyms |
Anti-hCD74 (clone11)
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | HLA class II histocompatibility antigen gamma chain (CD74) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Anti-CD74 ADC 12-13 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.20 ug/mL
|
Positive CD74 expression (CD74 +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | T lymphocytic leukemia | HuT 78 cells | CVCL_0337 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.63 ug/mL
|
Positive CD74 expression (CD74 +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | SU-DHL-6 cells | CVCL_2206 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 30.00 ug/mL | Negative CD74 expression (CD74 -) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
Anti-CD74 ADC 12-15 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.26 ug/mL
|
Positive CD74 expression (CD74 +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | T lymphocytic leukemia | HuT 78 cells | CVCL_0337 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
0.67 ug/mL
|
Positive CD74 expression (CD74 +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | SU-DHL-6 cells | CVCL_2206 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) | > 30.00 ug/mL | Negative CD74 expression (CD74 -) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
Anti-CD74 ADC 12-14 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
4.45 ug/mL
|
Negative CD74 expression (CD74 -) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | Renal cell carcinoma | 786-O cells | CVCL_1051 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
23.00 ng/mL
|
Positive CD74 expression (CD74 +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | Diffuse large B-cell lymphoma | SU-DHL-6 cells | CVCL_2206 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
55.00 ng/mL
|
Positive CD74 expression (CD74 +++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls 12-11, 12-12, and naked anti-hCD74 (LL1) control were assessed in HUT-78 an SUDHL-6 cells as well as 786-O cells.
|
||||
| In Vitro Model | T lymphocytic leukemia | HuT 78 cells | CVCL_0337 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.